Legend Biotech Ireland, a subsidiary of Legend Biotech, has announced an exclusive global license agreement with Novartis Pharma AG for the development of LB2102, a chimeric antigen receptor T-cell therapy targeting Delta-like ligand protein 3.
Advancing Groundbreaking Cell Therapies
Novartis, a leading pharmaceutical company, has been granted exclusive worldwide rights to manufacture and commercialize these innovative cell therapies. The agreement also allows Novartis to leverage its T-Charge platform for the manufacturing process.
Promising Clinical Development
Legend Biotech is spearheading the clinical development of LB2102 for the treatment of extensive stage small-cell lung cancer and large cell neuroendocrine carcinoma. This comes after the U.S. Food and Drug Administration (FDA) cleared the investigational new drug application in 2022. Recognizing its potential to address rare diseases and conditions, the FDA granted LB2102 Orphan Drug Designation in 2023.
Collaboration for Success
As part of the license agreement, Legend Biotech will conduct a Phase 1 clinical trial for LB2102 in the United States, while Novartis will oversee all other developmental activities. This collaboration ensures a comprehensive approach to bring these life-changing therapies to patients worldwide.
Milestones and Royalties
Under the terms of the agreement, Legend Biotech will receive an upfront payment of $100 million. Additionally, the company has the potential to earn up to $1.01 billion in milestone payments related to clinical trials, regulatory approvals, and commercial success. Furthermore, Legend Biotech will be eligible for tiered royalties based on product sales.